peptides for longevity

updated

longevity is where peptide marketing runs furthest ahead of the data. claims ranked by evidence quality.

several entries have narrow disease-specific approvals or established disease uses, including tesamorelin, elamipretide, rapamycin/sirolimus, and metformin. none is approved to extend healthy-human lifespan. epithalon remains a single-lab russian icon, MOTS-c opened a mitochondrial-derived-peptide research lane, and NAD+ is a dinucleotide cofactor rather than a peptide.

vilon and thymalin retain single-program, replication, null-result, and adverse-result boundaries; immune measurements do not establish lifespan benefit.

mitochondria, immune, and metabolic aging.

compounds with regulatory milestones, mechanistic specificity, or clinical-trial data on aging-adjacent biology.

  • tesamorelin (tier S) · ghrh analog, fda-approved nov 2010 as egrifta for hiv-associated lipodystrophy. · phase-3 visceral-fat reduction (15 to 18 percent across the lipo program, n>800, falutz nejm 2007) is aging-adjacent biology. the approved indication is hiv vat, not anti-aging. trial data does not transfer to healthy-adult longevity dosing.
  • ss-31 (tier A) · mitochondria-targeted tetrapeptide (elamipretide), hazel szeto lab cornell, developed by stealth biotherapeutics. · FDA accelerated approval landed september 2025 for Barth syndrome, a rare cardiolipin-deficiency cardiomyopathy. that validates a mitochondria-targeted peptide drug at the regulatory level. extrapolation to general longevity dosing is not in the approval data.
  • mots-c (tier B) · mitochondrial-derived peptide, lee group at usc, 2015. encoded inside the mitochondrial 12s rrna gene. · the first member of a new mechanistic class: peptides encoded inside the mitochondrial genome and signaling on metabolic flexibility. preclinical data is strong, human outcome data is still early.
  • humanin (tier C) · the first mitochondrial-derived peptide (hashimoto 2001), encoded inside the mt-rnr2 gene. cytoprotective biology in cells and rodents. · the founding member of the mdp class that mots-c later joined, first found keeping neurons alive in alzheimer's tissue. the preclinical cytoprotective signal is real and replicated and circulating levels fall with age, but there is no interventional human trial, which caps it at C.
  • thymosin alpha-1 (tier B) · 28-amino-acid immune peptide. approved as zadaxin in 35+ countries for chronic hepatitis b and as adjunct in sepsis. · immune aging is a real longevity topic and thymosin alpha-1 has a real hepatitis-b approval record. broad immune-support marketing is downstream and not supported by longevity-endpoint trial data.

where the story outruns replication.

compounds with high name recognition in longevity discussion and thinner independent evidence than the marketing suggests.

  • nad+ (tier B) · not a peptide. dinucleotide cofactor central to mitochondrial energy and repair pathways. · on the page because longevity searches surface it. oral precursor studies (nmn, nr) and boutique iv-drip claims are different evidence categories and should not be averaged. no controlled human outcome data supports iv nad+ for lifespan or healthspan.
  • epithalon (tier C) · khavinson-program tetrapeptide (ala-glu-asp-gly), st. petersburg institute of bioregulation and gerontology. · the iconic longevity peptide and the clearest example of single-lab dominance. khavinson's group ran the original telomerase and lifespan studies. western replication is minimal. iconic is not the same as settled.
  • pinealon (tier C) · khavinson tripeptide (glu-asp-arg) with neuroprotection claims. · belongs in the longevity conversation only because of the khavinson lineage. independent western validation is missing.
  • glutathione (tier D) · endogenous redox tripeptide (gamma-glu-cys-gly) tied to oxidative-stress biology. · oral and liposomal forms can shift glutathione biomarkers. detox marketing, anti-aging claims, and wellness-iv outcomes do not have controlled human evidence at the level the promise implies.
  • 5-amino-1mq (tier C) · not a peptide. small molecule NNMT inhibitor studied by subcutaneous administration in mice. · the foundational Biochemical Pharmacology study measured a 5.1 percent baseline weight loss in obese mice over 11 days. no human administration study was located, so longevity claims remain untested.
  • Rapamycin (tier D) · Rapamycin and sirolimus are the same active substance. Product-specific sirolimus approvals and mouse lifespan results do not establish healthy-human longevity or cognitive benefit. · Dietary rapamycin extended lifespan measures in UM-HET3 mice, but small human aging trials have not established a primary functional, visceral-fat, lifespan, broad healthspan, or cognitive benefit.
  • Metformin (tier D) · Metformin is an established type 2 diabetes drug. Its diabetes outcomes do not establish healthy-human lifespan, healthspan, cognition, or muscle benefit, and randomized geroscience trials have been null or unfavorable on their primary claims. · UKPDS supports selected long-term outcomes in overweight people with newly diagnosed type 2 diabetes. MASTERS, MET-PREVENT, and METFORAGING do not establish a general healthy-aging benefit.
  • vilon (tier D) · two amino acids from a russian lab, lysine joined to glutamic acid, sold on an anti-ageing claim. nobody has registered a trial of it in any registry checked, the three human papers state no sample size, and the strongest animal study reports more tumours. · two amino acids sold to slow ageing and to hold tumours back, and both claims come back weaker than the label. the one lifespan experiment that compared them head to head gave the survival gain to the sibling pineal peptide and reported no survival figure for this one. on tumours, three animal models favour it and the best-refereed study reports more mammary cancer. the human immune claim has never been tested at all.
  • thymalin (tier D) · a drug made from calf thymus glands, sold for immune support and to slow ageing. registered in the ussr in 1982 and never once entered into a trial registry. the largest human dataset belongs to the two men who made it. · a mixture of peptides extracted from calf thymus glands, registered as a medicine in the ussr in 1982 and sold for immune support and anti-ageing. it moves immune numbers: every group that has put it beside a control and counted t cells has watched them go up from baseline. the anti-ageing claim rests on one dataset of 266 older people, reported by the two men who developed the compound, published twice from that single cohort and unchecked by anyone else since. 44 years of published clinical reporting, and zero registered trials in any registry.

specific-question reference.

which longevity peptide has the strongest regulatory milestone?

ss-31 (elamipretide), FDA accelerated approval september 2025 for Barth syndrome, a rare cardiolipin-deficiency cardiomyopathy. tesamorelin has older FDA approval (november 2010) for HIV-associated visceral lipodystrophy. both are narrow indications. neither is an approval for healthy-adult anti-aging dosing.

which compound is most interesting mechanistically?

mots-c, identified by lee and cohen at usc in 2015. the first member of a class of peptides encoded inside the mitochondrial genome itself (the 12s rrna open reading frame), signaling on amp-kinase and metabolic flexibility. the human clinical record is still early.

why is epithalon not ranked higher?

the longevity claim depends on khavinson-lab literature with minimal independent western replication. iconic does not mean settled. the single-lab pattern is the weakness.

what is the safest way to read longevity claims?

as evidence tiers. approved narrow indication, controlled human trial, preclinical biology, mechanistic hypothesis, and marketing narrative are different categories that should not be averaged.

what the safety literature reports.

what safety gap matters most in longevity peptides?

duration. short-term and preclinical signals do not characterize chronic healthy-adult exposure. longevity dosing protocols imply years of use against trial data measured in weeks or months.

why is nad+ included if it is not a peptide?

longevity search traffic surfaces it, and excluding it leaves readers without a comparison. it is a dinucleotide cofactor, not a peptide. the iv-clinic outcome claim is not supported by controlled human data, and the page tiers it accordingly rather than pretending it fits the class.

what claim is intentionally avoided?

that any compound extends human lifespan. this page reports mechanisms, trial record, and regulatory status. it does not make lifespan promises.

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.